With one of the rationales identified behind the refractory nature of HER2+ BC after anti-HER2 treatment as upregulation of immune checkpoints such as PD-1/PD-L1 and CTLA-4, amending ICB-based treatment is thought to add therapeutic benefits in treating HER2+ BC (22, 27, 28). This evidence concerns the gene CTLA4 and breast cancer.